终末期肝病细胞治疗供体细胞来源的研究进展  

Advances in Cell Sources for the Treatment of End Stage Liver Disease

作　　者：孙筱[1] 于兵[1] 陈费[1] 王敏君[1] 何志颖[1] 胡以平[1] 

机构地区：[1]第二军医大学基础医学部细胞生物学教研室,上海200433

出　　处：《中国细胞生物学学报》2015年第5期740-745,共6页Chinese Journal of Cell Biology

基　　金：国家自然科学基金(批准号:31401166;31271474);中国博士后科学基金(批准号:2013M542434)资助的课题~~

摘　　要：许多因素所致的肝脏疾病都有可能发展为终末期肝病,而终末期肝病目前唯一有效的治疗方法就是原位肝移植。然而,由于受供体肝脏短缺等因素的限制,细胞治疗方法一直被临床上所期待。近年来,基于谱系重编程的诱导型肝干细胞和诱导型肝实质细胞的技术体系的出现,为解决肝脏疾病细胞治疗中细胞来源匮乏的问题提供了新的思路,也加速了肝脏疾病细胞治疗研究向临床转化的进程。该文介绍了肝脏疾病细胞治疗研究中供体细胞来源的现状,并重点介绍了谱系重编程获取肝系细胞的研究进展。Liver diseases caused by different factors can develop into end stage liver disease. Currently, orthotopic liver transplantation is considered to be the only effective treatment for end stage liver disease. However, it has been restricted by shortage of donor liver, immune rejection and other reasons. Cell therapy has emerged in recent decades as an alternative option for end stage liver disease. Especially, the lineage reprogramming technology, which was used to induce hepatic stem cells and hepatocyte-like cells, not only offers a new strategy to solve the shortage of liver cells, but also accelerates clinical transitional process of cell therapy. This review introduces the present situation on source of cells for liver disease treatment, and highlights the progress of hepatic cells obtained from lineage reprogramming.

关 键 词：终末期肝病 细胞移植 肝实质细胞 肝脏干细胞 谱系重编程 

分 类 号：R575[医药卫生—消化系统]